𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platelet activating factor (PAF) andlyso-PAF in psoriasis

✍ Scribed by M. R. Judge; R. M. Barr; A. I. Mallet; F. Courtney; A. Kobza Black; M. W. Greaves


Publisher
Springer-Verlag
Year
1994
Tongue
English
Weight
409 KB
Volume
286
Category
Article
ISSN
0340-3696

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Rabbit blastocysts accumulate platelet-a
✍ M. A. Jones; G. B. Kudolo; M. J. K. Harper πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 915 KB

## Abstract Platelet‐activating factor (1‐__O__‐alkyl‐2‐acetyl‐__sn__‐glycero‐3‐phosphorylcholine; PAF) is a very potent phospholipid, which has been demonstrated to stimulate smooth muscle and change vascular permeability. PAF has been detected in the rabbit preimplantation uterine endometrium and

Molecular modeling on platelet-activatin
✍ Carlos M. R. De Sant'anna; Ricardo Bicca De Alencastro; Carlos A. M. Fraga; Elie πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 885 KB

Platelet-activating factor (PAF) is an autacoid derived from cellular membrane phospholipids in response to chemical or physical stimuli. It has been identified as 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine; the alkyl group is composed of 16 or 18 carbon atoms in human cells. PAF can cause a se

Conformationally Restricted Analogs of P
✍ Paul HadvΓ‘ry; Thomas Weller πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 German βš– 636 KB

The synthesis of the five-membered cyclic phosphorodiamidic-acid derivatives 10 and 11 as well as the preparation of the six-membered cyclic phosphates 18, 19,22-25, and phosphoramidates 27-32 is described. The effects of these conformationally restricted platelet-activating factor analogs on rabbit

The specificity of the binding of platel
✍ Mary A. Smal; Brian A. Baldo; David G. Harle πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 510 KB

## Abstract Quantitative hapten inhibition experiments employing sheep anti‐PAF antibodies and selected PAF analogues were undertaken with the aim of defining the antigenic determinant structures complementary to the antibody combining sites. The most important fine structural features for inhibiti